Biometrics contract research organisation (CRO) Phastar has joined Lean Life Science’s Oncology Development Programme (ODP2).
The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
In collaboration with global pharma companies, Cancer Research UK’s Cancer Research Horizons, Manchester Cancer Research Centre (MCRC) and more than 20 specialist CROs, ODP2 aims to identify, de-risk and catalyse commercially viable UK-based innovations.
Phastar will be offering biometrics support, including statisticians, data scientists, data managers and programmers, as part of the scheme.
“ODP2 offers an opportunity for individuals and newer companies who do not necessarily have the benefit of a wealth of expertise to get drugs developed in the clinical trial setting, offering new oncology treatment options for patients,” commented Andrew MacGarvey, CEO, Phastar.
ODP2 is seeking applications from academics and early-stage companies with a defined oncology-focused innovation. It will provide access to expert scientific review, clinical study design, biometric data, technical gap analysis, financial and business value modelling, and integrated project planning.
Up to 100 oncology innovations will be selected by the Programme Faculty Panel, to participate in part one of the programme – a fully immersive one-day virtual masterclass.
Part two of ODP2 is a three-day deep dive into Lean Life Science’s approach to developing oncology assets and securing investment and is an opportunity to engage directly with pharma and CRO experts.
Part three, by application, will see selected participants work closely with the partners to create and validate the integrated plans necessary to ensure successful development and attract potential funding.
